L3VLUP
ProSign in

ALGN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALGNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALGN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterALGNLLY
Q3 202022 holders, $4.0bn33 holders, $14.1bn
Q4 202021 holders, $6.4bn29 holders, $17.3bn
Q1 202130 holders, $6.5bn24 holders, $23.0bn
Q2 202129 holders, $6.5bn24 holders, $27.8bn
Q3 202126 holders, $8.1bn31 holders, $29.9bn
Q4 202121 holders, $8.4bn31 holders, $34.7bn
Q1 202220 holders, $6.1bn24 holders, $35.3bn
Q2 202217 holders, $3.4bn33 holders, $42.7bn
Q3 202219 holders, $2.7bn31 holders, $43.4bn
Q4 202216 holders, $2.2bn31 holders, $46.6bn
Q1 202319 holders, $3.8bn33 holders, $44.3bn
Q2 202320 holders, $4.1bn37 holders, $59.6bn
Q3 202318 holders, $2.9bn44 holders, $67.6bn
Q4 202320 holders, $2.4bn45 holders, $73.6bn
Q1 202419 holders, $2.7bn41 holders, $95.3bn
Q2 202418 holders, $1.6bn43 holders, $110bn
Q3 202415 holders, $2.1bn45 holders, $107bn
Q4 202417 holders, $1.5bn46 holders, $93.9bn
Q1 202517 holders, $1.3bn42 holders, $98.4bn
Q2 202517 holders, $1.5bn43 holders, $93.2bn
Q3 202511 holders, $751m39 holders, $86.7bn
Q4 202514 holders, $1.0bn41 holders, $123bn
Q1 202610 holders, $1.3bn39 holders, $106bn
Q2 202610 holders, $1.9bn44 holders, $132bn
ALGN

Align Technology Inc

Holders
14
Reported value
$1.0bn
Buyers
23
Sellers
16

Breadth +7 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALGN (4)

ARK Investment Management LLC, Caxton Associates LLP, ExodusPoint Capital Management LP, Ruane Cunniff & Goldfarb LP

Only LLY (31)

Acadian Asset Management LLC, AllianceBernstein LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Rokos Capital Management LLP, Soros Fund Management LLC, and 6 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →